Key result
Patients undergoing solitary surgical aortic valve replacement with a Carpentier-Edwards Perimount bioprosthesis had a 15-year overall survival of 24%, compared to 32% in the matched background population.
Why the study?
Assessment of long-term survival after solitary SAVR is a key issue as newer techniques such as TAVR may have shorter durability.
Does solitary surgical aortic valve replacement with a Carpentier-Edwards Perimount bioprosthetic valve provide satisfactory long-term survival compared to the background population?
Observational (n=1,604)
Yes
Does solitary surgical aortic valve replacement with a Carpentier-Edwards Perimount bioprosthetic valve provide satisfactory long-term survival compared to the background population?
Absolute Event Rate: 24% vs 32%
p-value: p=<0.05
Solitary surgical aortic valve replacement with a Carpentier-Edwards Perimount bioprosthesis provides excellent long-term survival that matches the general population for up to 10 years.
Reduced 15-year survival after Perimount SAVR warrants caution in counseling; leaves open drivers of excess late mortality.
Abstract Background: This study describes the long-term survival, risk of reoperation and clinical outcomes for patients undergoing solitary surgical aortic valve replacement (SAVR) with a Carpentier-Edwards Perimount (CE-P) bioprosthetic in Denmark. The renewed interest in SAVR is based on the questioning regarding the long-term survival since new aortic replacement technique such as transcatheter aortic-valve replacement (TAVR) probably have shorter durability, why assessment of long-term survival could be a key issue for patients.Methods: From November 1999 to November 2015 a cohort of a total of 1604 patients aged 20-91 undergoing solitary SAVR with CE-P in Western Denmark was obtained November 2018 from the Western Danish Heart Registry (WDHR). The primary endpoint was long-term survival from all-cause mortality. Secondary endpoints were survival free from major adverse cardiovascular and cerebral events (MACCE), risk of reoperation, cause of late death, patient-prothesis mismatch, risk of AMI, stroke, pacemaker or ICD implantation and postoperative atrial fibrillation (POAF). Time-to event analysis was performed with Kaplan-Meier curve, cumulative incidence function was performed with Nelson-Aalen cumulative hazard estimates. Cox regression was applied to detect risk factors for death and reoperation.Results: In-hospital mortality was 2.7% and 30-day mortality at 3.4%. The 5-, 10- and 15-year survival from all-cause mortality was 77%, 52% and 24%, respectively. Survival without MACCE was 80% after 10 years. Significant risk factors of mortality were small valves, smoking and EuroSCORE II ≥4%. The risk of reoperation was <5% after 7.5 years and significant risk factors were valve prosthesis-patient mismatch and EuroSCORE II ≥4%.Conclusions: Patients operated with for aortic valve replacement with a Carpentier-Edwards Perimount valve shows a very satisfying long-term survival. Future research should aim to investigate biological valves long-term durability for comparison of different SAVR to different TAVR in long perspective.
No takes yet. Share an insight, caveat, or question.
Krasniqi et al. (2020) conducted an observational in Aortic valve disease requiring replacement (n=1,604). Carpentier-Edwards Perimount (CE-P) bioprosthesis vs. Matched background population was evaluated on 15-year survival from all-cause mortality (p=<0.05). Patients undergoing solitary surgical aortic valve replacement with a Carpentier-Edwards Perimount bioprosthesis had a 15-year overall survival of 24%, compared to 32% in the matched background population.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: